ArticleNeurology(R) neuroimmunology & neuroinflammation2022
Disease-Modifying Drugs for Multiple Sclerosis and Association With Survival.
Abstract read
In one paragraph
Article in Neurology(R) neuroimmunology & neuroinflammation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Polymorphisms in CLOCK and ARNTL/BMAL-1 genes in multiple sclerosis: a systematic review and meta-analysis.European journal of medical research · 2026Pooled it
- Deconfounded, quantitative microbiome profiling identifies robust multiple sclerosis markers and clinical covariate associations.Gut microbes · 2026Article
- Article
- Temporal Trends in the Incidence and Prevalence of Multiple Sclerosis in Sweden, 2001-2021.Neuroepidemiology · 2026Article
- Impact of cancer on multiple sclerosis-related healthcare and disease-modifying drug use: A multinational cohort study.Multiple sclerosis (Houndmills, Basingstoke, England) · 2026Article
- Could rituximab revolutionize multiple sclerosis treatment in Brazil? The missed opportunity for fewer relapses and lower costs.Lancet regional health. Americas · 2025Review
- Simultaneously Dealing With Immortal Time Bias and Residual Confounding: A Case Study of a High-Dimensional Propensity Score Approach With a Nested Case-Control Framework in Multiple Sclerosis Research.Pharmacoepidemiology and drug safety · 2025Article
- Mortality and causes of death for people with multiple sclerosis: a Finnish nationwide register study.Journal of neurology · 2025Article
- Stable excess mortality in a multiple sclerosis cohort diagnosed 1970-2010.European journal of neurology · 2024Article
- Narrative Review on the Use of Cladribine Tablets as Exit Therapy for Stable Elderly Patients with Multiple Sclerosis.Neurology and therapy · 2024Review
- Adverse Events Associated With Disease-Modifying Drugs for Multiple Sclerosis: A Multiregional Population-Based StudyNeurology · 2024Article
- Disease-modifying drugs, multiple sclerosis and infection-related healthcare use in British Columbia, Canada: a population-based study.Lancet regional health. Americas · 2024Article
- Multiple sclerosis disease-modifying drug use by immigrants: a real-world study.Scientific reports · 2023Article
- Association Between Anti-CD20 Therapies and COVID-19 Severity Among Patients With Relapsing-Remitting and Progressive Multiple Sclerosis.JAMA network open · 2023Article
- Neuroinflammatory disorders of the brain and inner ear: a systematic review of auditory function in patients with migraine, multiple sclerosis, and neurodegeneration to support the idea of an innovative 'window of discovery'.Frontiers in neurology · 2023Review
- Switching to second line MS disease-modifying therapies is associated with decreased relapse rate.Frontiers in neurology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Huah Shin NgFrom the Department of Medicine (H.S.N., F.Z., E.K., Y.Z., H.T.), Division of Neurology and the Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, Canada; Research Department of Primary Care & Population Health (E.K.), University College London, United Kingdom; College of Pharmacy and Nutrition (S.Y., C.E.), University of Saskatchewan Saskatoon; Health Quality Council (S.Y.), Saskatoon, SK; Department of Community Health Sciences (O.E.), Rady Faculty of Health Sciences, University of Manitoba, Winnipeg; Nova Scotia Health Authority and the Departments of Psychiatry (J.D.F.), Psychology and Neuroscience, and Medicine, Dalhousie University, Halifax; and Departments of Internal Medicine and Community Health Sciences (R.A.M.), Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada.ORCID https://orcid.org/0000-0001-8381-5253
Feng ZhuFrom the Department of Medicine (H.S.N., F.Z., E.K., Y.Z., H.T.), Division of Neurology and the Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, Canada; Research Department of Primary Care & Population Health (E.K.), University College London, United Kingdom; College of Pharmacy and Nutrition (S.Y., C.E.), University of Saskatchewan Saskatoon; Health Quality Council (S.Y.), Saskatoon, SK; Department of Community Health Sciences (O.E.), Rady Faculty of Health Sciences, University of Manitoba, Winnipeg; Nova Scotia Health Authority and the Departments of Psychiatry (J.D.F.), Psychology and Neuroscience, and Medicine, Dalhousie University, Halifax; and Departments of Internal Medicine and Community Health Sciences (R.A.M.), Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada.
Elaine KingwellFrom the Department of Medicine (H.S.N., F.Z., E.K., Y.Z., H.T.), Division of Neurology and the Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, Canada; Research Department of Primary Care & Population Health (E.K.), University College London, United Kingdom; College of Pharmacy and Nutrition (S.Y., C.E.), University of Saskatchewan Saskatoon; Health Quality Council (S.Y.), Saskatoon, SK; Department of Community Health Sciences (O.E.), Rady Faculty of Health Sciences, University of Manitoba, Winnipeg; Nova Scotia Health Authority and the Departments of Psychiatry (J.D.F.), Psychology and Neuroscience, and Medicine, Dalhousie University, Halifax; and Departments of Internal Medicine and Community Health Sciences (R.A.M.), Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada.
Shenzhen YaoFrom the Department of Medicine (H.S.N., F.Z., E.K., Y.Z., H.T.), Division of Neurology and the Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, Canada; Research Department of Primary Care & Population Health (E.K.), University College London, United Kingdom; College of Pharmacy and Nutrition (S.Y., C.E.), University of Saskatchewan Saskatoon; Health Quality Council (S.Y.), Saskatoon, SK; Department of Community Health Sciences (O.E.), Rady Faculty of Health Sciences, University of Manitoba, Winnipeg; Nova Scotia Health Authority and the Departments of Psychiatry (J.D.F.), Psychology and Neuroscience, and Medicine, Dalhousie University, Halifax; and Departments of Internal Medicine and Community Health Sciences (R.A.M.), Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada.
Okechukwu EkumaFrom the Department of Medicine (H.S.N., F.Z., E.K., Y.Z., H.T.), Division of Neurology and the Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, Canada; Research Department of Primary Care & Population Health (E.K.), University College London, United Kingdom; College of Pharmacy and Nutrition (S.Y., C.E.), University of Saskatchewan Saskatoon; Health Quality Council (S.Y.), Saskatoon, SK; Department of Community Health Sciences (O.E.), Rady Faculty of Health Sciences, University of Manitoba, Winnipeg; Nova Scotia Health Authority and the Departments of Psychiatry (J.D.F.), Psychology and Neuroscience, and Medicine, Dalhousie University, Halifax; and Departments of Internal Medicine and Community Health Sciences (R.A.M.), Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada.
Charity EvansFrom the Department of Medicine (H.S.N., F.Z., E.K., Y.Z., H.T.), Division of Neurology and the Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, Canada; Research Department of Primary Care & Population Health (E.K.), University College London, United Kingdom; College of Pharmacy and Nutrition (S.Y., C.E.), University of Saskatchewan Saskatoon; Health Quality Council (S.Y.), Saskatoon, SK; Department of Community Health Sciences (O.E.), Rady Faculty of Health Sciences, University of Manitoba, Winnipeg; Nova Scotia Health Authority and the Departments of Psychiatry (J.D.F.), Psychology and Neuroscience, and Medicine, Dalhousie University, Halifax; and Departments of Internal Medicine and Community Health Sciences (R.A.M.), Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada.
John D FiskFrom the Department of Medicine (H.S.N., F.Z., E.K., Y.Z., H.T.), Division of Neurology and the Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, Canada; Research Department of Primary Care & Population Health (E.K.), University College London, United Kingdom; College of Pharmacy and Nutrition (S.Y., C.E.), University of Saskatchewan Saskatoon; Health Quality Council (S.Y.), Saskatoon, SK; Department of Community Health Sciences (O.E.), Rady Faculty of Health Sciences, University of Manitoba, Winnipeg; Nova Scotia Health Authority and the Departments of Psychiatry (J.D.F.), Psychology and Neuroscience, and Medicine, Dalhousie University, Halifax; and Departments of Internal Medicine and Community Health Sciences (R.A.M.), Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada.
Ruth Ann MarrieFrom the Department of Medicine (H.S.N., F.Z., E.K., Y.Z., H.T.), Division of Neurology and the Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, Canada; Research Department of Primary Care & Population Health (E.K.), University College London, United Kingdom; College of Pharmacy and Nutrition (S.Y., C.E.), University of Saskatchewan Saskatoon; Health Quality Council (S.Y.), Saskatoon, SK; Department of Community Health Sciences (O.E.), Rady Faculty of Health Sciences, University of Manitoba, Winnipeg; Nova Scotia Health Authority and the Departments of Psychiatry (J.D.F.), Psychology and Neuroscience, and Medicine, Dalhousie University, Halifax; and Departments of Internal Medicine and Community Health Sciences (R.A.M.), Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada.
Yinshan ZhaoFrom the Department of Medicine (H.S.N., F.Z., E.K., Y.Z., H.T.), Division of Neurology and the Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, Canada; Research Department of Primary Care & Population Health (E.K.), University College London, United Kingdom; College of Pharmacy and Nutrition (S.Y., C.E.), University of Saskatchewan Saskatoon; Health Quality Council (S.Y.), Saskatoon, SK; Department of Community Health Sciences (O.E.), Rady Faculty of Health Sciences, University of Manitoba, Winnipeg; Nova Scotia Health Authority and the Departments of Psychiatry (J.D.F.), Psychology and Neuroscience, and Medicine, Dalhousie University, Halifax; and Departments of Internal Medicine and Community Health Sciences (R.A.M.), Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada.
Helen TremlettFrom the Department of Medicine (H.S.N., F.Z., E.K., Y.Z., H.T.), Division of Neurology and the Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, Canada; Research Department of Primary Care & Population Health (E.K.), University College London, United Kingdom; College of Pharmacy and Nutrition (S.Y., C.E.), University of Saskatchewan Saskatoon; Health Quality Council (S.Y.), Saskatoon, SK; Department of Community Health Sciences (O.E.), Rady Faculty of Health Sciences, University of Manitoba, Winnipeg; Nova Scotia Health Authority and the Departments of Psychiatry (J.D.F.), Psychology and Neuroscience, and Medicine, Dalhousie University, Halifax; and Departments of Internal Medicine and Community Health Sciences (R.A.M.), Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada. helen.tremlett@ubc.ca.ORCID https://orcid.org/0000-0001-5804-2535
Funding
CIHR FDN-159934CIHR PJT-156363
Abstract
BACKGROUND AND
objectivesWe examined the association between the disease-modifying drugs (DMDs) for multiple sclerosis (MS) and survival in a multiregion population-based study.
methodsWe accessed multiple administrative health databases from 4 Canadian provinces. Persons with MS were identified and followed from the most recent of the first MS or demyelinating event or January 1, 1996 (index date), until death, emigration, or December 31, 2017. Association between the first-generation and second-generation DMDs and all-cause mortality was examined using stratified Cox proportional hazard models, reported as adjusted hazard ratios (aHRs). Timing of DMD initiation was explored, with findings reported at 2, 5, or 10 years postindex date, representing very early, early, or late initiation.
resultsWe identified 35,894 persons with MS; 72% were female. The mean age at index date was 44.5 years (SD = 13.6). The total person-years of follow-up while DMD-exposed was 89,180, and total person-years while unexposed was 342,217. Compared with no exposure, exposure to any DMD or to any first-generation DMD was associated with a 26% lower hazard of mortality (both aHRs 0.74; 95% CI 0.56-0.98), while any second-generation DMD exposure was associated with a 33% lower hazard (aHR 0.67; 95% CI 0.46-0.98). Earlier DMD initiation (beta-interferon or glatiramer acetate vs no exposure) was associated with a significant mortality effect ( DISCUSSION: Our study demonstrates an association between the DMDs for MS and improved survival in the real-world setting.
Indexed as
Multiple SclerosisCanadaDatabases, FactualFemaleGlatiramer AcetateHumansInterferon-betaMaleGlatiramer AcetateInterferon-beta
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.